| Literature DB >> 22172095 |
Matthias Guckenberger1, Reinhart A Sweeney, John C Flickinger, Peter C Gerszten, Ronald Kersh, Jason Sheehan, Arjun Sahgal.
Abstract
BACKGROUND: Spinal radiosurgery is a quickly evolving technique in the radiotherapy and neurosurgical communities. However, the methods of spine radiosurgery have not been standardized. This article describes the results of a survey about the methods of spine radiosurgery at five international institutions.Entities:
Mesh:
Year: 2011 PMID: 22172095 PMCID: PMC3286433 DOI: 10.1186/1748-717X-6-172
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Patient specific factors influencing indication for spine SBRT
| UHW | UPMC | UofT | UVAMC | RSMC | |
|---|---|---|---|---|---|
| Use of a predictive scoring system for OS | Yes, Mizumoto Score | No | Life expectancy ≥ 3 months | Patients with widespread CNS and systemic disease are excluded | No |
| Histology of primary tumor | No treatment of highly radiosensitive histologies | Avoid relatively radiosensitive histologies | No myeloma unless previously radiated | No treatment of radiosensitive histologies | No relevant factor |
| Status of primary tumor | Yes, part of the Mizumoto Score | No relevant factor | Yes, for estimation of life expectancy | No relevant factor | No relevant factor |
| Presence of visceral metastases | Yes, part of the Mizumoto Score | No relevant factor | Yes, for estimation of life expectancy | Yes, see above | No relevant factor |
| Age | Yes, part of the Mizumoto Score | No relevant factor | No relevant factor | No relevant factor | No relevant factor |
| Performance status of patient | Yes, part of the Mizumoto Score | Exclusion of patients with extremely poor performance status | Must be able to tolerate immobilization for 45 min. | KPS should be ≥70 | KPS must be ≥60 |
| Comorbidities of patient | No relevant factor | No relevant factor | No relevant factor | No relevant factor | No relevant factor |
| Interval between primary tumor and spinal metastases | No relevant factor | No relevant factor | No relevant factor | No relevant factor | No relevant factor |
Target specific factors influencing indication for spine SBRT
| UHW | UPMC | UofT | UVAMC | RSMC | |
|---|---|---|---|---|---|
| Location of vertebral metastases (C, T, L) | No relevant factor | No relevant factor | No relevant factor | No relevant factor | No relevant factor |
| Number of vertebras in one target volume | Maximum of 3 levels | Maximum of 3 levels | Maximum of 3 levels | Maximum of 3 levels | Maximum of 2 levels |
| Extent of vertebral metastases | Symptomatic and progressive cord compression is contraindication. | Significant spinal cord compression associated with myelopathy is contraindication. | Symptomatic cord compression is contraindication. | Symptomatic cord compression is contraindication. | Symptomatic cord compression is contraindication. |
| Epidural involvement | No relevant factor | No relevant factor | Surgery if high grade epidural involvement present | Minimum of 2 mm of clearance between the gross metastastic disease and the spinal cord | No relevant factor |
| Stability of metastatic vertebra | Surgical opinion sought first | Instability is preferably treated with stabilization procedure | Surgical opinion sought first | Instability is preferably treated with stabilization procedure | Instability is preferably treated with stabilization procedure |
| Lytic or sclerotic metastasis | No relevant factor | No relevant factor | No relevant factor | No relevant factor | No relevant factor |
| Vertebral compression fracture | Symptomatic compression fracture are discussed with neurosurgeons in advance | Compression fracture causing kyphosis and pain will be treated BEFORE radiosurgery if possible | Surgical opinion sought first | Compression fracture causing marked kyphosis or instability will be treated with stabilization procedure first | Compression fracture is preferably treated with stabilization procedure |
| Location of metastasis relative to other organs at risk | No relevant factor | No relevant factor | No relevant factor | No relevant factor | No relevant factor |
Imaging for staging & target definition
| UHW | UPMC | UofT | UVAMC | RSMC | |
|---|---|---|---|---|---|
| Staging examinations prior to SBRT/SRS | Oncologic staging is required | None | MRI spine | None | None |
| Slice thickness of Planning CT | 1.5 mm | 1.25 mm | 1 mm | 1 to 1.5 mm | 2 mm |
| MRI used for target definition | Yes | Yes | Yes | Yes | Yes |
| Dedicated Planning MRI | Yes | No | Yes | Yes | Yes |
| Slice thickness of planning MRI | 2 mm | 1.25 mm | 1 mm | 1.2 mm | 3 mm/1.25 mm |
| MRI sequence used for target definition, | T1 with and w/o contrast; T2 | T1 with contrast; T2 | T1 w/o contrast volumetric VIBE; T2 volumetric SPACE | T1 with contrast volume acquisition | T1 with and w/o |
| Dedicated FDG-PET/PET-CT for target definition | Rarely | Yes | No | Rarely | Yes |
Target and organs-at-risk definition
| UHW | UPMC | UofT | UVAMC | RSMC | |
|---|---|---|---|---|---|
| Imaging modality, which is used for GTV definition | MRI and CT | MRI and CT, FDG-PET if available | MRI and CT | CT and MRI | CT, MRI and FDG-PET |
| Use of an anatomical target volume concept | Anatomical two dose-level target volume concept | Anatomical target volume concept | Anatomical target volume concept | Anatomical target volume concept | Anatomical target volume concept |
| GTV to PTV safety margin | 3 mm | 2 mm; 3 mm in the sacrum. | 2 mm | 2 mm | None |
| Protocol if PTV overlaps with the. spinal cord | Two dose-level approach; | PTV within 1 mm to the spinal cord is excluded from the PTV | PTV is limited by the cord or thecal sac for cauda equina | If this occurs, we either operate to resect part of the tumor or fractionate the radiation. | GTV drawn to edge of OAR |
| Treatment of the vertebra superior and inferior to the metastatic vertebra | No | No | No | No | No |
| Imaging modality for definition of the spinal cord | Spinal cord in MRI | Spinal cord in MRI | Spinal cord in MRI | Spinal cord in MRI | Spinal canal in CT |
| Delineation of the spinal cord in cranio-caudal direction | At least 1 level above and below PTV | 1 level above and below PTV | At least 1 level above and below PTV | 1 level above and below PTV | 1 level above and below PTV |
| Safety margins around the spinal cord in axial directions | 1 mm | 1 mm | 1.5 mm | No | 2 mm anterior and 1 mm lateral |
| Delineation of the cauda equina | Thecal sac | Thecal sac | Thecal sac | Thecal sac | Thecal sac |
| Delineation other OARs (e.g. kidney) | No application of safety margins | No application of safety margins | No application of safety margins | No application of safety margins | No application of safety margins |
Doses and fractionation
| UHW | UPMC | UofT | UVAMC | RSMC | |
|---|---|---|---|---|---|
| Use of single fraction radiosurgery | No, all patients are treated with either five or ten fractions | Single fraction radiosurgery for 95% of the patients unless very near to spinal cord. | Majority is treated with two or three fractions and specific cases for single fraction | Majority is treated with a single fraction of radiosurgery, occasionally up to 3 fractions | No, majority are treated with three fractions with treatments given one week apart. |
| Criteria for selection of hypo-fractionated regimes | Selection of fractionation scheme based on life expectancy using the Mizumoto Score | Fractionated protocols in: | Fractionated protocols after prior radiation | If it represents the only site of disease, we use 30 Gy in 3 | |
| Schema 1: # fractions and single fraction dose | Good life expectancy: | 16-24 Gy in 1; | 20-24 Gy in 1; | 18 to 24 Gy in 1; | 24 Gy in 3 |
| Schema 2: # fractions and single fraction dose | Intermediate life expectancy: | 24 - 27 Gy in 2-3 | 24 Gy in 3 | 30 Gy in 3 | |
| Schema 3: # fractions and single fraction dose | 30 Gy in 3 | 18 Gy in 3 | |||
| Dose prescription | D90 | D90 | ICRU point | D90 | D90 |
* a simultaneous integrated boost (SIB) was used at the UHW with two dose levels to PTV -macroscopic and PTV -elective
Spinal cord tolerance doses
| Tolerance doses Spinal Cord | |||||
|---|---|---|---|---|---|
| UHW | Dmax to 0.1 cc | 23.75 Gy | 35 Gy | ||
| UPMC | Dmax | 11 Gy | 18 Gy | ||
| UofT | Dmax | 10 Gy | 17.5 Gy | 22 Gy | |
| UVAMC | D10 | 10 Gy | 15 Gy | 20 Gy | |
| RSMC | 2 cc | 18 Gy | |||
| UHW | Dmax to 0.1 cc | 25 Gy | 37.5 Gy | ||
| UPMC | Dmax | 12 Gy | 18 Gy | ||
| UofT | Dmax | 12 Gy | 18 Gy | 23 Gy | |
| UVAMC | D10 | 12 Gy | 15 Gy | 20 Gy | |
| RSMC | 2 cc | 24 Gy | |||
Treatment planning
| UHW | UPMC | UofT | UVAMC | RSMC | |
|---|---|---|---|---|---|
| Treatment planning system | Pinnacle | Pinnacle | Pinnacle | Varian Eclipse, Tomotherapy, | 1. Elekta/CMS XiO, |
| Linac model/MLC leaf width | Elekta Synergy S/4 mm | Synergy S/4 mm | Elekta Synergy S/4 mm | Elekta Synergy S, | Elekta Synergy S/4 mm |
| IMRT or VMAT treatment planning | Both | IMRT | Both | VMAT | Both |
| If step-and-shoot IMRT: number of beams | 9 beams on average | 9 to 14, but most are 12 beams | 9 - 11 beams | 10 beams | 10 beams |
| If VMAT: number of arcs | 1-2 arcs | Not applicable | 1 arc | 1-3 arcs | 1. one arc 120-140 segments |
| Full or partial VMAT arc | 360 degrees | 360 degrees | 360 degrees | 360 degree arcs | 1. VMAT 350 deg arc |
| Photon energy | 6 or 10 mV depending on location | 6 MV | 6 MV | 6 MV | 6 MV |
| Dosimetric parameters for plan acceptance | No strict acceptance criteria. | Usually V90 | CTV V80 of at least 80-90% | No strict acceptance criteria | Generally D90 |
Patient (re-)positioning and IGRT
| UHW | UPMC | UofT | UVAMC | RSMC | |
|---|---|---|---|---|---|
| Treatment prone or supine | Supine | Supine | Supine | supine | Supine |
| Immobilization device | Cervical: Thermoplastic mask; | Cervical down to T5: aquaplast face mask; | Cervical down to T2/3 s frame; | Cervical: Thermoplastic mask; | Cervical: Aquaplast mask with Accuform support secured to modified S-frame; |
| Image guidance technology | Cone-beam CT | Cone-beam CT | Cone-beam CT | Cone-beam CT | Cone-beam CT |
| Frequency of IGRT | Daily | Daily | Daily | Daily | Daily |
| Correction of rotational set-up errors | Yes - Hexapod couch | Yes - Hexapod couch | Yes - Hexapod couch | Yes - Hexapod couch | Yes - Hexapod couch |
| Action level for correction of set-up errors | 1 mm translation, | 1 mm translation, | 1 mm translation, | 2 mm translation, | 1 mm translation, |
| Second imaging after couch adjustment prior to treatment | Yes | Yes | Yes | Yes | Yes |
| Methods for intra-fractional patient monitoring | None | Cone-beam CT imaging after one and two thirds through the treatment | One to two intra-treatment Cone-beam CT scans | One intra-fraction cone-beam CT scan half-way through treatment | Typical one or two mid treatment cone-beam CTs |
| Imaging after treatment | Yes | No | Yes | Yes | No |
Follow-up and response evaluation
| UHW | UPMC | UofT | UVAMC | RSMC | |
|---|---|---|---|---|---|
| Place of follow-up | In clinic | In clinic | In clinic | In clinic | In clinic |
| Definition of local control | No progression on serial imaging. | No progression on serial imaging. | No progression on serial imaging. | No progression on serial imaging. | No progression on serial imaging. |
| Imaging modalities required for definition of local control | MRI if possible | MRI if possible | MRI if possible | MRI if possible | MRI/PET |
| System for pain scoring | Visual analogue scale | Visual analogue scale | N/A unless of study then the Brief Pain Inventory | Visual analogue scale | NRS-11 |
| Frequency of FU examinations | Every three months, every six months after 1 year | 1 month, then 3 months, then 6, 12, and then yearly. | Every 2-3 months | 3 month intervals for the first year | Every 3 months |